Does Wuhan Hospital sell Mobocertinib?

Mobocertinib (Mobocertinib) is a new type of oral drug that belongs to the category of targeted therapy drugs. Its primary use is to treat EGFR (epidermal growth factor receptor)-mutated non-small cell lung cancer (NSCLC). Mobosetinib is a third-generation EGFR inhibitor specifically designed to target lung cancer patients with the EGFR T790M mutation, a common resistance mutation in lung cancer treatment.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.

The efficacy of mobosetinib is based on its targeting ofEGFRmutants. EGFR is an important signaling pathway protein involved in the regulation of cell growth and division. EGFRMutantNSCLC The EGFR gene mutation will cause this signaling pathway to be abnormally active and promote the abnormal growth of cancer cells. Mobosetinib controls and slows the growth of lung cancer by inhibiting these abnormally active EGFR mutants to prevent the proliferation and spread of cancer cells.

The efficacy data of mobosetinib mainly come from clinical trials, such as the "EXPERT" (NCT02716116) trial. Early trial results show that mobosetinib has good efficacy in patients with EGFR T790M mutation-positive NSCLC, including high progression-free survival (PFS) and overall response rate (ORR). These data demonstrate that mobosetinib can effectively prolong disease control and survival in patients.